New drug XTX202 tested in patients with advanced cancers
NCT ID NCT05052268
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XTX202
What this could lead to
If successful, XTX202 could offer a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 95 participants, so results may not apply to all patients. Side effects and lack of tumor shrinkage are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Atlantic Health System/Morristown Medical Center
Morristown, New Jersey, 07960, United States
-
Carolina BioOncology Institute
Huntersville, North Carolina, 28078, United States
-
Georgetown University Medical Center
Washington D.C., District of Columbia, 20007, United States
-
HealthPartners Cancer Center at Regions Hospital
Saint Paul, Minnesota, 55101, United States
-
Hoag Memorial Hospital Presbyterian- Newport Beach
Newport Beach, California, 92663, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
Rutgers Cancer Institute of NJ
New Brunswick, New Jersey, 08903, United States
-
Sarah Cannon Research Institute
Nashville, Tennessee, 37203, United States
-
The Ohio State University Wexner Medical Center James Cancer Hospital and Solove Research Institute
Columbus, Ohio, 43210, United States
-
UC San Diego Moores Cancer Center
La Jolla, California, 92093, United States
-
UPMC Hillman Cancer Center Pavilion
Pittsburgh, Pennsylvania, 15213, United States
-
University of California Los Angeles
Los Angeles, California, 90095, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States